Iridex Enrolls First Patient in MicroPulse TLT Study in Collaboration with Imperial College Healthcare NHS Trust

Iridex and Imperial College Healthcare NHS Trust in London announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse Transscleral Laser Therapy (TLT) using the Iridex Cyclo G6 Laser and the MicroPulse P3 Delivery Device. The aim of the partnership is to establish a large-scale enrollment platform to advance clinical research.

"The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward multicenter participation enabling a large-scale view and significant in-country impact of our MicroPulse technology," David I. Bruce, President and CEO of Iridex, said in a company news release.

The study, titled "MicroPulse Transscleral Laser Therapy: A Prospective UK Study," is set to expand Iridex’s global clinical portfolio through funding essential components of the 3-year study and providing a custom-designed and secure database management system, according to Iridex. 

“We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma. Expansion to include other units will be crucial in advancing glaucoma treatment in the UK," said Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust. "Our partnership with Iridex is key to enhancing this study's reach and impact.” 

The Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulse TLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. The registry and study is structured for expanded participation from other UK providers to join the program and build enrollment for large patient cohorts.